Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 4/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.30 |
| ▸ | NRP1 | O14786 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075993 | 0.83 | ACE (0.43) | PIN1ACE | |
| SCHEMBL28727117 | 0.81 | ACE (0.58) | PIN1ACEPOLB | |
| SCHEMBL247111 | 0.81 | ACE (0.58) | PIN1ACEPOLB | |
| SCHEMBL1022805 | 0.77 | PIN1 (0.42) | PIN1ACEPOLB | |
| SCHEMBL29624413 | 0.76 | MMP2 (0.42) | PIN1ACEMMP2ANPEP | |
| SCHEMBL5787348 | 0.70 | PIN1 (0.43) | PIN1ACENRP1 | |
| SCHEMBL2687375 | 0.69 | POLB (0.35) | PIN1POLB | |
| SCHEMBL17966432 | 0.69 | ATM (0.36) | PIN1POLBMMP2ANPEP | |
| SCHEMBL3403167 | 0.69 | POLB (0.35) | PIN1POLB | |
| SCHEMBL3400563 | 0.68 | POLB (0.34) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102791693-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2012-11-21 | — | — | CN | claimed |
| US-8119673-B2 | Compounds 148 | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| US-20090318517-A1 | Novel Compounds 148 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | TFPI, TFPI2, SPINT2 | PIN1 827/4885ACE 60/4885POLB 4327/4885 |
| US-20090318517-A1 | Novel Compounds 148 | SERPINB1, SPINT2, TFPI | PIN1 1135/4885ACE 83/4885POLB 4185/4885 |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | TFPI, TFPI2, ADAMTS1 | PIN1 916/4885ACE 94/4885POLB 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.